Ipilimumab’s long-term survival edge confirmed in melanoma
October 29, 2013|Internal Medicine News
Author and Disclosure Information
AT THE EUROPEAN CANCER CONGRESS 2013
Dr. Hodi reported having no financial disclosures and no outside funding for the pooled analysis. The National Cancer Institute conducted three of the phase II studies, and Bristol-Myers Squibb conducted the remaining studies. Prof. Gore reported serving on the speakers bureaus for Pfizer, Roche, Novartis, and Bristol-Myers Squibb, and on the advisory boards for Pfizer, Roche, and Astellas.
